Research and development
pipeline

With our research and development pipeline, we target some of the highest-needing therapeutic areas.

NEUROTROPHINES

NERVE GROWTH FACTOR (NGF)

The Nerve Growth Factor (NGF) is a polypeptide essential for the survival and growth of sympathetic and sensory neurons and for differentiation of neurons in the central nervous system. The protein is highly conserved across species, with human NGF (hNGF) and murine NGF (mNGF) sharing 90% homology in amino-acid sequence of mature protein.

NGF binds two distinct classes of receptors:

1) tropomyosin receptor kinase A (TrkA), a transmembrane tyrosine kinase that is also known as high-affinity NGF receptor, and

2) low affinity NGF receptor (p75 LNGFR), also called p75 neurotrophin receptor (p75NTR).

NGF and its receptors are expressed, in addition to the other compartments, both in the anterior and the posterior segment of the eye, and play a crucial role in the physiopathology of several ocular diseases.

RHNGF
Neurotrophic Keratitis

  • DISCOVERY

  • PRECLINICAL

  • PHASE I

  • PHASE II

  • PHASE III

  • PHASE IV

DRUG DISCOVERY

RALOXIFENE

Raloxifene hydrochloride is the hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid-lowering effects and activity against osteoporosis. Scientific literature reports the antiviral activity of raloxifene against Ebola virus, Hepatitis C virus, HBV, and Zika virus, and clinical efficacy as an adjuvant antiviral treatment of chronic hepatitis C, thus suggesting that the drug is a promising candidate for antiviral treatments.

Through the Exscalate supercomputing platform, and in the context of the funded EU grant EXSCALATE4COV (E4C) headed by Dompé Drug Discovery team, raloxifene was selected as a promising molecule to be studied as a possible treatment for mild to moderate COVID-19 patients.

RALOXIFENE
Mild to moderate COVID-19

  • DISCOVERY

  • PRECLINICAL

  • PHASE I

  • PHASE II

  • PHASE III

  • PHASE IV

CHEMOKINES

REPARIXIN

Reparixin is a non-competitive allosteric inhibitor of CXCL8 receptors, CXCR1 and CXCR2, able to inhibit the intracellular signal transduction events activated by the binding of CXCL8 to CXCR1 and CXCR2. The binding site hypothesis derived through computational studies was confirmed by alanine scanning mutagenesis, and a region in the transmembrane of CXCR1 and CXCR2 was identified.

REPARIXIN
Severe Covid-19 Pneumonia

  • DISCOVERY

  • PRECLINICAL

  • PHASE I

  • PHASE II

  • PHASE III

  • PHASE IV

REPARIXIN
Breast Cancer

  • DISCOVERY

  • PRECLINICAL

  • PHASE I

  • PHASE II

  • PHASE III

  • PHASE IV

DIABETOLOGY

LADARIXIN

Ladarixin is a non-competitive allosteric inhibitor of CXCL8 receptors, CXCR1 and CXCR2, able to inhibit the intracellular signal transduction events activated by CXCL8 without affecting binding of CXCL8 to CXCR1 and CXCR2. Chemical computational studies and alanine-replacement mutagenesis studies have identified the binding site of Ladarixin on CXCR1/2 in the transmembrane domain of the receptors.

LADARIXIN
TYPE 1 DIABETES ONSET

  • DISCOVERY

  • PRECLINICAL

  • PHASE I

  • PHASE II

  • PHASE III

  • PHASE IV

Dompé farmaceutici S.p.A. Single shareholder company / Share capital € 50.000.000,00
REA MI 289519 - A registered company in Milan, Italy / Tax code and VAT number IT00791570153

Close